Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition

Author

P. Manca

View on Semantic Scholar

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Optimizing neoadjuvant immunotherapy in rectal cancer.

The integration of immune checkpoint inhibitors (ICIs) into neoadjuvant strategies is increasingly being studied in locally advanced rectal cancer (LARC), to improve complete response (CR), organ preservation, and potentially overall survival (OS). However, the clinical impact of conventional PD-1 blockade still remain...

G. Pennoni, G. Rebecchi, Miao-Miao Gou et al. · 0 citations
Open access Aug 2026

Epigenetic evolution of colorectal cancer and its microenvironment reveals new vulnerabilities

Epigenetics is central to tumorigenesis, but the co-evolution of the cancer epigenome and its microenvironment is severely understudied. Here, we measure chromatin accessibility and transcriptome, at single cell resolution, of a set of normal colon, primary colorectal cancers and metastases, and identify recurrent epig...

Alexandra Livanova, Luca Azzolin, F. Cambuli et al. · 0 citations
Review Open access Jul 2026

Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis

Findings support ctDNA RAS status as a potential biomarker of benefit from anti-EGFR-based therapy in mCRC, although methodological standardization and prospective validation remain necessary.

M. Valladares-Ayerbes, Pilar García Alfonso, V. Heinemann et al. · 0 citations
Open access Aug 2026

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies

In cetuximab–avelumab therapy, the absence of liver metastases and longer anti-EGFR-free interval might represent potential biomarkers and single-agent cetuximab activity is not influenced by clinical factors.

D. Ciardiello, G. Martini, F. Pietrantonio et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.